Desmopressin mitochondrial dysfunction has been identified as a key cellular effect in human glioma cells, according to new research published in Drug Development Research. The study shows that desmopressin induces mitochondrial fragmentation and functional impairment in U87 MG glioma cells through activation of the CaMKII–Drp1 signaling pathway.
Desmopressin is a synthetic analogue of vasopressin that is widely used in clinical practice to treat bleeding disorders and diabetes insipidus. However, its effects on cancer cell biology have remained poorly understood. This new research provides mechanistic insight into how desmopressin interacts with intracellular signaling systems in tumor cells.
Desmopressin mitochondrial dysfunction and cell signaling
The researchers found that exposure to desmopressin disrupted the normal balance of mitochondrial dynamics in U87 MG glioma cells. Instead of maintaining elongated, interconnected mitochondrial networks, treated cells showed excessive mitochondrial fragmentation, a hallmark of cellular stress and dysfunction.
This process was traced to the activation of calcium/calmodulin-dependent protein kinase II (CaMKII), which in turn stimulated dynamin-related protein 1 (Drp1). Drp1 is a key regulator of mitochondrial fission, and its overactivation drives the breakdown of mitochondrial structure.
Impact of desmopressin mitochondrial dysfunction on glioma cells
Mitochondrial fragmentation was accompanied by reduced mitochondrial membrane potential and impaired energy metabolism, indicating that mitochondrial dysfunction affects not only structure but also function. These changes can influence cell survival, proliferation, and sensitivity to stress, all of which are critical factors in cancer progression.
Because mitochondria play a central role in regulating apoptosis and metabolic adaptation, disruption of their function may alter how glioma cells respond to therapeutic interventions.
Why desmopressin mitochondrial dysfunction matters
The findings highlight the importance of evaluating non-oncology drugs for unexpected cellular effects in cancer models. Understanding how desmopressin mitochondrial dysfunction occurs via CaMKII–Drp1 signaling could help researchers better predict off-target effects and explore potential therapeutic repurposing strategies.
The study adds to growing evidence that drug-induced changes in mitochondrial dynamics can significantly influence cancer cell behavior, reinforcing the need for careful molecular evaluation during drug development and translational research.
